` VINC (Vincerx Pharma Inc) vs S&P 500 Comparison - Alpha Spread

VINC
vs
S&P 500

Over the past 12 months, VINC has underperformed S&P 500, delivering a return of -99% compared to the S&P 500's 4% growth.

Stocks Performance
VINC vs S&P 500

Loading

Performance Gap
VINC vs S&P 500

Loading
VINC
S&P 500
Difference

Performance By Year
VINC vs S&P 500

Loading
VINC
S&P 500
Add Stock

Competitors Performance
Vincerx Pharma Inc vs Peers

S&P 500
VINC
ABBV
AMGN
GILD
VRTX
Add Stock

Vincerx Pharma Inc
Glance View

Market Cap
1.4m USD
Industry
Biotechnology

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2020-03-10. The Company’s small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The firm's antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds addressing known and novel oncology targets. The Company’s bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.

VINC Intrinsic Value
Not Available
Back to Top